相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
C. Potter et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
J. P. Leombruno et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis
W. H. Bos et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Alterations of the Synovial T Cell Repertoire in Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis
Tineke Cantaert et al.
ARTHRITIS AND RHEUMATISM (2009)
Human lupus, fewer Treg cells indeed: comment on the article by Venigalla et al
Makoto Miyara et al.
ARTHRITIS AND RHEUMATISM (2009)
Current concepts in the pathogenesis of early rheumatoid arthritis
Arthur G. Pratt et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2009)
The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium
C. A. Wijbrandts et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Disease Activity-Guided Rituximab Therapy in Rheumatoid Arthritis The Effects of Re-Treatment in Initial Nonresponders Versus Initial Responders
Rogier M. Thurlings et al.
ARTHRITIS AND RHEUMATISM (2008)
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice
W. Kievit et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor a inhibitors in rheumatoid arthritis
Francesca Bobbio-Pallavicini et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response
K. N. Verpoort et al.
ARTHRITIS AND RHEUMATISM (2006)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
GJ Wolbink et al.
ARTHRITIS AND RHEUMATISM (2006)
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study
F Atzeni et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
C Alessandri et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution -: Data from the Stockholm tumor necrosis factor α followup registry
RF van Vollenhoven et al.
ARTHRITIS AND RHEUMATISM (2003)
分享论文
